thenewsfacts.com
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
thenewsfacts.comthenewsfacts.com
Font ResizerAa
Search
  • Home
  • Latest News
  • Trending News
  • Entertainment
  • Technology
  • Sports
  • Business
  • Health
Follow US
© thenewsfacts : All Rights Reserved.

Home » COVAXIN Safety Assured: Bharat Biotech Puts Safety First

Latest News

COVAXIN Safety Assured: Bharat Biotech Puts Safety First

TheNewsFacts
Last updated: May 2, 2024 10:33 pm
TheNewsFacts
Share
COVAXIN safety First
COVAXIN Safety Assured: Bharat Biotech Puts Safety First
SHARE

May 2, 2024: In the interest of public health, Bharat Biotech reaffirmed the safety of India’s COVAXIN®️, developed using Whole-Virion Inactivated Vero Cell derived platform technology in a post. With a focus on safety above all else, COVAXIN®️ has undergone rigorous testing, including trials involving over 27,000 individuals within India.

As stated informed to public at large by the firm, inactivated vaccines do not replicate and are therefore unlikely to revert and cause pathological effects. They contain dead virus, incapable of infecting people but still able to instruct the immune system to mount a defensive reaction against an infection.

Each step of its evaluation has been conducted meticulously, ensuring that safety remains paramount. Continuous monitoring is in place to guarantee safety throughout its use.

Importantly, there have been no reports of serious side effects associated with the vaccine, such as blood clots or heart issues. This commitment to safety backs Bharat Biotech’s dedication to protecting public health with safety first approach.

Key Reasons that validate the safety first approach of COVAXIN

COVAXIN®️ was developed with a single-minded focus on safety first, followed by efficacy.

Covaxin
Bharat Biotech Says Covaxin was developed with Safety First Approach
  • COVAXIN®️ was the only COVID-19 vaccine in the Govt of India’s COVID-19 immunisation program to have conducted efficacy trials in India.
  • COVAXIN®️ was evaluated in more than 27,000 subjects as part of its licensure process.
  • It was licensed under restricted use in clinical trial mode, where detailed safety reporting was carried out for several hundred thousand subjects.
  • Safety of COVAXIN®️ was also evaluated by the Ministry of Health, Govt of India.
  • Ongoing safety monitoring (pharmacovigilance) was continued throughout the product life cycle of COVAXIN®️.

All the above studies and safety follow-up activities have demonstrated an excellent safety record for COVAXIN®️, without any vaccine-associated incidents of blood clots, Thrombocytopenia, TTS, VITT, pericarditis, myocarditis, etc.,

As seasoned innovators and product developers, the Bharat Biotech team was well aware that, while the efficacy of COVID-19 vaccines may be short-lived, the impact on patient safety could last a lifetime.

Hence safety is the primary focus for all our vaccines.

TAGGED: Bharat Biotech, Bharat Biotech Covid Vaccine, Covaxin, Covaxin Public Interest Message, covid19 vaccine, Dr. Krishna Ella
Share This Article
Twitter Email Copy Link Print
Previous Article Free Foundational Course in Counselling Hyderabad Big Turnout for Free Foundational Counselling Course in Hyderabad
Next Article Hamida Banu Google Doodle Hamida Banu’s Inspiring Wrestling Legacy Inspires Google Doodle

Your Trusted Source for Accurate and Timely Updates!

We're committed to providing accurate and unbiased news as it unfolds, earning the trust of a large audience. Stay informed with our news updates on the latest events and trends, keeping you ahead of the curve.
FacebookLike
TwitterFollow
InstagramFollow

Popular Posts

Indian Batsman have a remarkable run in 2022 Cricket ODI Season

Cricket ODI: Team India has been shining in ODI's and what has been remarkable has…

By TheNewsFacts

Yuzvendra Chahal: Bowlers Need Help, Simon Taufel Says No

Yuzvendra Chahal and Former ICC Elite Panel umpire Simon Taufel have a debate goind on.…

By TheNewsFacts

Novak Djokovic’s 24th Grand Slam: A Night of Legends, Timeless Mastery

September 11, 2023: In a thrilling climax to the 2023 US Open, Novak Djokovic etched…

By TheNewsFacts

You Might Also Like

Bhool Chuk Maaf Box Office Report
Latest News

Bhool Chuk Maaf Crosses ₹54 Cr Globally in 7 Days

By NewsFacts Bureau
Bharat Biotech HILLCHOL
Latest News

Bharat Biotech’s Oral Cholera Vaccine HILLCHOL Demonstrates Success in Phase III Clinical Studies

By TheNewsFacts
Biovet Lumpy Skin Disease Vaccine Launched
Latest News

BIOLUMPIVAXIN: New Vaccine Now Available to Protect Livestock from LSD

By NewsFacts Bureau
Google AI First Accelerator 2025 India
Latest News

Google Opens 2025 India AI First Accelerator: $17B Opportunity for Startups

By NewsFacts Bureau
thenewsfacts thenewsfacts

About US


TheNewsFacts: Brings you the interesting facts, news facts and updates from India an the world across politics, tech, entertainment, business, tending, and more. We deliver what you love to read.
Top Categories
  • Latest News
  • Trending News
  • Paris Olympics 2024
  • Sports
  • Entertainment
  • Business
  • Technology
Usefull Links
  • About The News Facts
  • Latest News
  • Privacy Policy
  • Editorial Policy
  • Disclaimer
  • Contact Us
Follow us
Facebook Twitter Instagram

© thenewsfacts. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?